Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.
Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Key Topics Covered:
1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.2. Gefapixant: Merck & Co., Inc.
11.3. GLPG1690: Galapagos NV
11.4. LT-1001: LTT Bio-Pharma
11.5. BG00011: Biogen Inc.
11.6. BMS-986020: Bristol-Myers Squibb
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.8. Pamrevlumab: FibroGen
11.9. PBI4050: ProMetic Life Sciences
11.10. PRM 151: Promedior, Inc.
11.11. Tipelukast: MediciNova
11.12. TD139: Bristol-Myers Squibb
11.13. VAY736: Novartis
11.14. TAS-115: Taiho Pharmaceutical
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
14. Market Drivers of IPF
15. Market Barriers of IPF
16.1. Report Methodology
For more information about this report visit https://www.researchandmarkets.com/research/slfg3c/idiopathic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006229/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Respiratory Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/13/2018 04:51 PM/DISC: 06/13/2018 04:51 PM